Endothelin a receptor antagonist reduces renal vasoconstriction induced by mechanical manipulation of renal artery

被引:0
|
作者
Watarai, Y [1 ]
Yoshioka, M [1 ]
Tanada, K [1 ]
Seki, T [1 ]
Saito, H [1 ]
Koyanagi, T [1 ]
机构
[1] Hokkaido Univ, Sch Med, Dept Urol, Sapporo, Hokkaido 0608638, Japan
关键词
endothelin; vasoconstriction; mechanical manipulation; endothelin A receptor;
D O I
10.1159/000030510
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study was to make a model of renal vasoconstriction induced by mechanical manipulation of the renal artery and to investigate the influence of endothelin (ET) in renal vasoconstriction. Renal arteries of anesthetized rats were stretched with a 30-gram weight for 5 min, and released. Renal blood flow (RBF) was monitored with a laser flowmeter. To determine the role of ET, a selective ETA receptor antagonist, BQ-123 (0.1 and 1 mg/kg) was administered into the aorta. The manipulation was invariably followed by a flow reduction of about 57% after temporary hyperemia. RBF returned to the basal level 5 min after the release. BQ-123 partially, but significantly, inhibited the mechanical manipulation-induced reduction of RBF in a dose-dependent manner. These results suggest that endogeneous ET may play an important role in renal vasoconstriction induced by mechanical manipulation of the renal artery. Copyright (C) 2000 S. Karger AG, Basel.
引用
收藏
页码:121 / 125
页数:5
相关论文
共 50 条
  • [31] Involvement of endogenous endothelin-1 in exercise-induced redistribution of tissue blood flow - An endothelin receptor antagonist reduces the redistribution
    Maeda, S
    Miyauchi, T
    Iemitsu, M
    Tanabe, T
    Irukayama-Tomobe, Y
    Goto, K
    Yamaguchi, I
    Matsuda, M
    CIRCULATION, 2002, 106 (17) : 2188 - 2193
  • [32] Differential effects of the mixed ETA/ETB-receptor antagonist bosentan on endothelin-induced bronchoconstriction, vasoconstriction and prostacyclin release
    Martin, C
    Held, HD
    Uhlig, S
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2000, 362 (02) : 128 - 136
  • [33] A preventive effect of a selective endothelin-A receptor antagonist, S-0139, on the erythropoietin-induced reduction of the renal cortical blood flow
    Ishikawa, A
    Suzuki, K
    Fujita, K
    UROLOGICAL RESEARCH, 1999, 27 (05): : 312 - 314
  • [34] A preventive effect of a selective endothelin-A receptor antagonist, S-0139, on the erythropoietin-induced reduction of the renal cortical blood flow
    Akira Ishikawa
    Kazuo Suzuki
    Kimio Fujita
    Urological Research, 1999, 27 : 312 - 314
  • [35] Dependence of renal excretory response to ETA receptor blockade on renal endothelin (ET) synthesis
    Girchev, R
    Baecker, A
    Markova, P
    Kramer, HJ
    AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (05) : 8A - 8A
  • [36] Regression of renal vascular fibrosis by endothelin receptor antagonism
    Boffa, JJ
    Tharaux, PL
    Dussaule, JC
    Chatziantoniou, C
    HYPERTENSION, 2001, 37 (02) : 490 - 496
  • [37] Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets during endotoxic shock
    Chin, A
    Radhakrishnan, J
    Fornell, L
    John, E
    JOURNAL OF PEDIATRIC SURGERY, 2002, 37 (03) : 482 - 487
  • [38] Treatment with a combined endothelin A/B-receptor antagonist does not prevent chronic renal allograft rejection in rats
    Braun, C
    Conzelmann, T
    Vetter, S
    Schaub, M
    Back, WE
    Kirchengast, M
    Tullius, SG
    Schnülle, P
    van der Woude, FJ
    Rohmeiss, P
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 36 (04) : 428 - 437
  • [39] Endothelin-1 levels and conduit artery mechanical properties in end-stage renal disease
    Dammers, R
    Hoeks, APG
    Tordoir, JHM
    Welten, RJTJ
    Hamulyák, K
    Kooman, JP
    Kitslaar, PJEHM
    BLOOD PURIFICATION, 2005, 23 (03) : 190 - 195
  • [40] The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction
    Ferro, CJ
    Haynes, WG
    Johnston, NR
    Lomax, CC
    Newby, DE
    Webb, DJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (04) : 377 - 383